Dr. Cowan on Efficacy and Safety of BCMA CAR T-Cells in Multiple Myeloma

Video

Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine, and hematologist/oncologist at Seattle Cancer Care Alliance, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

A phase I study has treated a total of 7 patients thus far; these patients have been heavily pretreated with a median of 10 prior regimens. Approximately 75% of patients had a high-risk feature at the time of study entry. One patient died at day 33 post-CAR T-cell therapy due to cytokine release syndrome (CRS) and concurrent fungal infection, says Cowman. After that incident, the protocol was modified and no additional dose-limiting toxicities have been observed since then. The most common grade ≥3 adverse events observed with the treatment were neutropenic fever (70%), CRS (100%), and neurotoxicity (70%).

An 100% overall response rate was observed with the therapy with no relapses. The median follow-up is 20 weeks, but the patient currently with the longest- follow-up has shown no evidence of disease for ≥1 year, concludes Cowan. However, longer follow-up and of more patients are needed to determine if the durability of response is improved in patients treated with BCMA CAR T-cell therapy.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.